Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205373 | 0.97 | ARG1 (0.32) | ARG1CA2CA1 | |
| SCHEMBL7204059 | 0.83 | CA2 (0.33) | ARG1CA2 | |
| SCHEMBL13668109 | 0.81 | CA2 (0.37) | ARG1CA2 | |
| SCHEMBL29596201 | 0.78 | CA2 (0.52) | ARG1CA2 | |
| SCHEMBL12141473 | 0.75 | APEX1 (0.30) | — | |
| SCHEMBL8315548 | 0.74 | ARG1 (0.33) | ARG1CA2 | |
| SCHEMBL3089492 | 0.73 | — | — | |
| SCHEMBL2625547 | 0.73 | NLRP3 (0.38) | — | |
| SCHEMBL8556536 | 0.72 | — | — | |
| SCHEMBL8555178 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4071239-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-12 | — | — | EP | disclosed |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| WO-2021132627-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | 大日本住友製薬株式会社 | 2021-07-01 | — | — | WO | disclosed |
| EP-3191471-B1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | TEN30 BIOSCIENCES, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | TEN30 BIOSCIENCES, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-6124494-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6103922-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-6103923-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-6100426-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0811600-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0811599-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0806203-A2 | Anti-viral compositions | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806409-A1 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806410-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806408-A1 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | HCLS1, KIT, MCL1 | ARG1 371/4885CA2 1709/4885CA1 864/4885 |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | PIK3R5, PIK3CA, PIK3R1 | ARG1 1860/4885CA2 3404/4885CA1 4619/4885 |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | APP, PSEN2, PSEN1 | ARG1 593/4885CA2 1773/4885CA1 43/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | ARG1 2845/4885CA2 564/4885CA1 439/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ARG1 3078/4885CA2 721/4885CA1 447/4885 |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | APP, PSEN2, PSEN1 | ARG1 520/4885CA2 1712/4885CA1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.